Информация предназначена только для профессионалов в области здравоохранения.
Вы можете зайти как пользователь социальных сетей
РУДН
Список исп. литературыСкрыть список 1. GBD 2016 Disease and Injury Incidence and Prevalence Collaborators. Global, regional, and national incidence, prevalence, and years lived with disability for 328 diseases and injuries for 195 countries, 1990–2016: a systematic analysis for the Global Burden of Disease Study 2016. Lancet. 2017. 390:1211–1259. doi: 10.1016/S0140-6736(17)32154-2 2. Howes O.D., McCutcheon R., Agid O., de Bartolomeis A., van Beveren N.J., Birnbaum M.L. et al. Treatment-resistant schizophrenia: treatment response and resistance in psychosis (TRRIP) working group consensus guidelines on diagnosis and terminology. Am J Psychiatry. 2017.174:216–229. doi: 10.1176/appi.ajp.2016.16050503 3. Leucht S., Corves C., Arbter D., Engel R.R., Li C., Davis J.M. Second-generation versus first-generation antipsychotic drugs for schizophrenia: a meta-analysis. Lancet. 2009.373:31–41. doi: 10.1016/S0140-6736(08)61764-X 4. Harvey P.D., Strassnig M. Predicting the severity of everyday functional disability in people with schizophrenia: cognitive deficits, functional capacity, symptoms, and health status. World Psychiatry. 2012.11:73–79. doi: 10.1016/j.wpsyc.2012.05.004 5. Fleischhacker W.W., Arango C., Arteel P., Barnes T.R., Carpenter W., Duckworth K. et al. Schizophrenia–time to commit to policy change. Schizophr Bull. 2014. 40(Suppl. 3):S165–194. doi: 10.1093/schbul/sbu006 6. Galderisi S., Rossi A., Rocca P., Bertolino A., Mucci A., Bucci P. et al. The influence of illness-related variables, personal resources and context-related factors on real-life functioning of people with schizophrenia. World Psychiatry. 2014. 13:275–287. doi: 10.1002/wps.20167 7. Green M.F., Horan W.P., Lee J., McCleery A., Reddy L.F., Wynn J.K. Social disconnection in schizophrenia and the general community. Schizophr Bull. 2018. 44:242–249. doi: 10.1093/schbul/sbx082 8. Harvey P.D., Strassnig M.T., Silberstein J. Prediction of disability in schizophrenia: symptoms, cognition, and self-assessment. J Exp Psychopathol. 2019. 10:2043808719865693. doi: 10.1177/2043808719865693 9. Jääskeläinen E., Juola P., Hirvonen N., McGrath J.J., Saha S., Isohanni M. et al. A systematic review and meta-analysis of recovery in schizophrenia. Schizophr Bull. 2013. 39:1296–1306. doi: 10.1093/schbul/sbs130 10. Zipursky R.B., Agid O. Recovery, not progressive deterioration, should be the expectation in schizophrenia. World Psychiatry. 2015. 14:94–96. doi: 10.1002/wps.20194 11. Vita A., Barlati S. Recovery from schizophrenia: is it possible? Curr Opin Psychiatry. 2018. 31:246–55. doi: 10.1097/YCO.0000000000000407 12. Owen M.J., Sawa A., Mortensen P.B. Schizophrenia. Lancet. 2016. 388:86–97. doi: 10.1016/S0140-6736(15)01121-6 13. Stilo S.A., Murray R.M. Non-genetic factors in schizophrenia. Curr Psychiatry Rep. 2019. 21:100. doi: 10.1007/s11920-019-1091-3 14. Correll C.U., Schooler N.R. Negative symptoms in schizophrenia: a review and clinical guide for recognition, assessment, and treatment. Neuropsychiatr Dis Treat. 2020. 16:519–34. doi: 10.2147/NDT.S225643 15. Galderisi S., Rucci P., Mucci A., Rossi A., Rocca P., Bertolino A. et al. The interplay among psychopathology, personal resources, context-related factors and real-life functioning in schizophrenia: stability in relationships after 4 years and differences in network structure between recovered and non-recovered patients. World Psychiatry. 2020. 19:81–91. doi: 10.1002/wps.20700 16. Maj M., van Os J., De Hert M,. Gaebel W., Galderisi S., Green M.F. et al. The clinical characterization of the patient with primary psychosis aimed at personalization of management. World Psychiatry. 2021. 20:4–33. doi: 10.1002/wps.20809 17. Santo-Angles A., Salvador R., Gomar J.J., Guerrero-Pedraza A., Ramiro N., Tristany J. et al. Interindividual variability of functional connectome in schizophrenia. Schizophr Res. 2021. 235:65–73. doi: 10.1016/j.schres.2021.07.010 18. Gaebel W., Zielasek J. Schizophrenia in 2020: trends in diagnosis and therapy. Psychiatry Clin Neurosci. 2015. 69:661–673. doi: 10.1111/pcn.12322 19. Gaebel W., Riesbeck M., Larach V.W., Falkai P., Zielasek J. Trends in schizophrenia diagnosis and treatment. In: Javed A, Fountoulakis KN, editors. Advances in Psychiatry. Cham: Springer International Publishing.2019. p. 603–619. 20. McCutcheon R.A., Krystal J.H., Howes O.D. Dopamine and glutamate in schizophrenia: biology, symptoms and treatment. World Psychiatry. 2020. 19:15– 33. doi: 10.1002/wps.20693 21. Perrottelli A., Giordano G.M., Brando F., Giuliani L., Mucci A. EEG-based measures in at-risk mental state and early stages of schizophrenia: a systematic review. Front Psychiatry. 2021.12:653642. doi: 10.3389/fpsyt.2021. 653642 22. Galderisi S., Rossi A., Rocca P., Bertolino A., Mucci A., Bucci P. et al. Pathways to functional outcome in subjects with schizophrenia living in the community and their unaffected first-degree relatives. Schizophr Res. 2016.175:154–160. doi: 10.1016/j.schres.2016.04.043 23. Galderisi S., Rucci P., Kirkpatrick B., Mucci A., Gibertoni D., Rocca P. et al. Interplay among psychopathologic variables, personal resources, context-related factors, and real-life functioning in individuals with schizophrenia: a network analysis. JAMA Psychiatry. 2018. 75:396–404. doi: 10.1001/jamapsychiatry.2017.4607 24. Galderisi S., Kaiser S., Bitter I., Nordentoft M., Mucci A., Sabe M. et al. EPA guidance on treatment of negative symptoms in schizophrenia. Eur Psychiatry. 2021. 64:e21. doi: 10.1192/j.eurpsy.2021.13 25. Austin S.F., Mors O., Budtz-Jørgensen E., Secher R.G., Hjorthøj C.R., Bertelsen M. et al. Long-term trajectories of positive and negative symptoms in first episode psychosis: a 10 year follow-up study in the OPUS cohort. Schizophr Res. 2015. 168:84–91. doi: 10.1016/j.schres.2015.07.021 26. Tripathi A., Kar S.K., Shukla R. Cognitive deficits in schizophrenia: understanding the biological correlates and remediation strategies. Clin Psychopharmacol Neurosci. 2018.16:7–17. doi: 10.9758/cpn.2018.16.1.7 27. Harvey P.D., Isner E.C. Cognition, social cognition, and functional capacity in early-onset schizophrenia. Child Adolesc Psychiatr Clin N Am. 2020. 29:171–182. doi: 10.1016/j.chc.2019.08.008 28. Vesterager L., Christensen T., Olsen B.B., Krarup G., Melau M., Forchhammer H.B. et al. Cognitive and clinical predictors of functional capacity in patients with first episode schizophrenia. Schizophr Res. 2012. 141:251–256. doi: 10.1016/j.schres.2012.08.023 29. Feldman R. What is resilience: an affiliative neuroscience approach. World Psychiatry. 2020. 19:132–150. doi: 10.1002/wps.20729 30. Altamura A., Fagiolini A., Galderisi S., Rocca P., Rossi A. Integrated treatment of schizophrenia. 2015. 21:168–193. 31. Acosta F.J., Hernandez J.L., Pereira J., Herrera J., Rodriguez C.J. Medication adherence in schizophrenia. World J Psychiatry. 2012. 2:74–82. doi: 10.5498/wjp.v2.i5.74 32. Morrison A.P., Law H., Carter L., Sellers R., Emsley R., Pyle M. et al. Antipsychotic drugs versus cognitive behavioural therapy versus a combination of both in people with psychosis: a randomised controlled pilot and feasibility study. Lancet Psychiatry. 2018. 5:411–423. doi: 10.1016/S2215-0366(18)30096-8 33. Higashi K., Medic G., Littlewood K.J., Diez T., Granström O., De Hert M. Medication adherence in schizophrenia: factors influencing adherence and consequences of nonadherence, a systematic literature review. Therap Adv Psychopharmacol. 2013. 3:200–218. doi: 10.1177/2045125312474019 34. Fervaha G., Agid O., Takeuchi H., Lee J., Foussias G., Zakzanis K.K. et al. Extrapyramidal symptoms and cognitive test performance in patients with schizophrenia. Schizophr Res. 2015. 161:351–356. doi: 10.1016/j.schres.2014.11.018 35. Monteleone P., Cascino G., Monteleone A.M., Rocca P., Rossi A., Bertolino A. et al. Prevalence of antipsychotic-induced extrapyramidal symptoms and their association with neurocognition and social cognition in outpatients with schizophrenia in the “real-life”. Prog Neuropsychopharmacol Biol Psychiatry. 2021. 109:110250. doi: 10.1016/j.pnpbp.2021.110250 36. MacKenzie N.E., Kowalchuk C., Agarwal S.M., Costa-Dookhan K.A., Caravaggio F., Gerretsen P. et al. Antipsychotics, metabolic adverse effects, and cognitive function in schizophrenia. Front Psychiatry. 2018. 9:622. doi: 10.3389/fpsyt.2018.00622 37. Fond G., Berna F., Boyer L., Godin O., Brunel L., Andrianarisoa M. et al. Benzodiazepine long-term administration is associated with impaired attention/working memory in schizophrenia: results from the national multicentre FACE-SZ data set. Eur Arch Psychiatry Clin Neurosci. 2018. 268:17–26. doi: 10.1007/s00406-017-0787-9 38. Joshi Y.B., Thomas M.L., Braff D.L., Green M.F., Gur R.C., Gur R.E. et al. Anticholinergic Medication Burden-Associated Cognitive Impairment in Schizophrenia. Am J Psychiatry. 2021. 178:838–847. doi: 10.1176/appi.ajp. 2020.20081212 39. Khan W.U., Ghazala Z., Brooks H.J., Subramaniam P., Mulsant B.H., Kumar S. et al. The impact of anticholinergic burden on functional capacity in persons with schizophrenia across the adult life span. Schizophr Bull. 2021. 47:249–257. doi: 10.1093/schbul/sbaa093 40. Mucci A., Galderisi S., Gibertoni D., Rossi A., Rocca P., Bertolino A. et al. Factors associated with real-life functioning in persons with schizophrenia in a 4-year follow-up study of the Italian network for research on psychoses. JAMA Psychiatry. 2021. 78:550–559. doi: 10.1192/j.eurpsy.2021.135 41. Moura B.M., Isvoranu A.M., Kovacs V., van Rooijen G., van Amelsvoort T., Simons C.J.P. et al. The puzzle of functional recovery in schizophrenia-spectrum disorders-replicating a network analysis study. Schizophr Bull. 2022. 48:871–880. doi: 10.1093/schbul/sbac018 42. Chien W.T., Leung S.F., Yeung F.K., Wong W.K. Current approaches to treatments for schizophrenia spectrum disorders, part II: psychosocial interventions and patient-focused perspectives in psychiatric care. Neuropsychiatr Dis Treat. 2013. 9:1463–1481. doi: 10.2147/NDT.S49263 43. Chien W.T., Yip A.L. Current approaches to treatments for schizophrenia spectrum disorders, part I: an overview and medical treatments. Neuropsychiatr Dis Treat. 2013. 9:1311–1332. doi: 10.2147/NDT.S37485 44. Morin L., Franck N. Rehabilitation interventions to promote recovery from schizophrenia: a systematic review. Front Psychiatry. 2017. 8:100. doi: 10.3389/fpsyt.2017.00100 45. Barlati S., Deste G., Galluzzo A., Perin A.P., Valsecchi P., Turrina C. et al. Factors associated with response and resistance to cognitive remediation in schizophrenia: a critical review. Front Pharmacol. 2018. 9:1542. doi: 10.3389/fphar.2018.01542 46. Sarin F., Wallin L. Cognitive model and cognitive behavior therapy for schizophrenia: an overview. Nord J Psychiatry. 2014. 68:145–153. doi: 10.3109/08039488.2013.789074 47. Nowak I., Sabariego C., Switaj P., Anczewska M. Disability and recovery in schizophrenia: a systematic review of cognitive behavioral therapy interventions. BMC Psychiatry. 2016. 16:228. doi: 10.1186/s12888-016-0912-8 48. Laws K.R., Darlington N., Kondel T.K., McKenna P.J., Jauhar S. Cognitive behavioural therapy for schizophrenia - outcomes for functioning, distress and quality of life: a meta-analysis. BMC Psychology. 2018. 6:32. doi: 10.1186/s40359-018-0243-2 49. Turner D.T., McGlanaghy E., Cuijpers P., van der Gaag M., Karyotaki E., MacBeth A. A Meta-analysis of social skills training and related interventions for psychosis. Schizophr Bull. 2018. 44:475–491. doi: 10.1093/ schbul/sbx146 50. Browne J., Mueser K.T., Pratt S.I. Chapter 17 - social skills training for persons with schizophrenia. In: Nangle D.W., Erdley C.A., Schwartz-Mette R.A., editors. Social Skills Across the Life Span. Academic Press. 2020. p. 329–342. 51. Lutgens D., Gariepy G., Malla A. Psychological and psychosocial interventions for negative symptoms in psychosis: systematic review and meta-analysis. Br J Psychiatry. 2017. 210:324–332. doi: 10.1192/bjp.bp.116.197103 52. Yeo H., Yoon S., Lee J., Kurtz M.M., Choi K. A meta-analysis of the effects of social-cognitive training in schizophrenia: the role of treatment characteristics and study quality. BrJ Clin Psychol. 2022. 61:37–57. doi: 10.1111/bjc.12320 53. Wykes T. Cognitive remediation – where are we now and what should we do next? The Journal of Psychopathol. 2018. 24:57–61. 54. Cella M., Price T., Corboy H., Onwumere J., Shergill S., Preti A. Cognitive remediation for inpatients with psychosis: a systematic review and meta-analysis. Psychol Med. 2020. 50:1062–1076. doi: 10.1017/ S0033291720000872 55. Kambeitz-Ilankovic L., Betz L.T., Dominke C., Haas S.S., Subramaniam K., Fisher M. et al. Multi-outcome meta-analysis (MOMA) of cognitive remediation in schizophrenia: revisiting the relevance of human coaching and elucidating interplay between multiple outcomes. Neurosci Biobehav Rev. 2019. 107:828–845. doi: 10.1016/j.neubiorev.2019.09.031 56. Vita A., Barlati S., Ceraso A., Deste G., Nibbio G., Wykes T. Acceptability of cognitive remediation for schizophrenia: a systematic review and meta-analysis of randomized controlled trials. Psychol Med. 2022.1–11. doi: 10.1017/S0033291722000319 57. Vita A., Barlati S., Ceraso A., Nibbio G., Ariu C., Deste G. et al. Effectiveness, core elements, and moderators of response of cognitive remediation for schizophrenia a systematic review and meta-analysis of randomized clinical trials. JAMA Psychiatry. (2021) 78:848–858. doi: 10.1001/jamapsychiatry.20 21.0620 58. Glenthøj L.B., Mariegaard L.S., Fagerlund B., Jepsen J.R.M., Kristensen T.D., Wenneberg C. et al. Effectiveness of cognitive remediation in the ultra-high risk state for psychosis. World Psychiatry. 2020. 19:401–402. doi: 10.1002/wps.20760 59. Correll C.U., Galling B., Pawar A., Krivko A., Bonetto C., Ruggeri M. et al. Comparison of early intervention services vs treatment as usual for early- phase psychosis: a systematic review, meta-analysis, and meta-regression. JAMA Psychiatry. 2018. 75:555–565. doi: 10.1001/jamapsychiatry.2018.0623 60. Singh S.P., Javed A. Early intervention in psychosis in low- and middle-income countries: a WPA initiative. World Psychiatry. 2020. 19:122. doi: 10.1002/wps.20708 61. Keshavan M.S., Eack S. Cognitive Enhancement in Schizophrenia and Related Disorders. Cambridge University Press.2019. https://doi.org/10.1017/ 9781108163682 62. Leucht S., Tardy M., Komossa K., Heres S., Kissling W., Salanti G. et al. Antipsychotic drugs versus placebo for relapse prevention in schizophrenia: a systematic review and meta-analysis. Lancet. 2012. 379:2063–2071. doi: 10.1016/S0140-6736(12)60239-6 63. DeRosse P., Nitzburg G.C., Blair M., Malhotra A.K. Dimensional symptom severity and global cognitive function predict subjective quality of life in patients with schizophrenia and healthy adults. Schizophr Res. 2018. 195:385–390. doi: 10.1016/j.schres.2017.10.018 64. Cullen B.A., McGinty E.E., Zhang Y., dosReis S.C., Steinwachs D.M., Guallar E. et al. Guideline-concordant antipsychotic use and mortality in schizophrenia. Schizophr Bull. 2012. 39:1159–1168. doi: 10.1093/schbul/sbs097 65. Liu N.H., Daumit G.L., Dua T., Aquila R., Charlson F., Cuijpers P. et al. Excess mortality in persons with severe mental disorders: a multilevel intervention framework and priorities for clinical practice, policy and research agendas. World Psychiatry. 2017. 16:30–40. doi: 10.1002/wps.20384 66. Pringsheim T., Gardner D., Addington D., Martino D., Morgante F., Ricciardi L. et al. The assessment and treatment of antipsychotic-induced Akathisia. Can J Psychiatry. 2018. 63:719–729. doi: 10.1177/0706743718760288 67. Verdoux H., Quiles C., Bon L., Chéreau-Boudet I., Dubreucq J., Legros-Lafarge E. et al. Characteristics associated with self-reported medication adherence in persons with psychosis referred to psychosocial rehabilitation centers. Eur Arch Psychiatry Clin Neurosci. 2021. 271:1415–1424. doi: 10.1007/s00406-020-01207-x 68. Taipale H., Tanskanen A., Mehtälä J., Vattulainen P., Correll C.U., Tiihonen J. 20-year follow-up study of physical morbidity and mortality in relationship to antipsychotic treatment in a nationwide cohort of 62,250 patients with schizophrenia (FIN20). World psychiatry. 2020. 19:61–68. doi: 10.1002/wps. 20699 69. Tsoutsoulas C., Mulsant B.H., Kalache S.M., Kumar S., Ghazala Z., Voineskos A.N. et al. The influence of medical burden severity and cognition on functional competence in older community-dwelling individuals with schizophrenia. Schizophr Res. 2016. 170:330–335. doi: 10.1016/j.schres.2015.12.009 70. Baandrup L., Fagerlund B., Glenthoj B. Neurocognitive performance, subjective well-being, and psychosocial functioning after benzodiazepine withdrawal in patients with schizophrenia or bipolar disorder: a randomized clinical trial of add-on melatonin versus placebo. Eur Arch Psychiatry Clin Neurosci. (2017) 267:163–171. doi: 10.1007/s00406-016-0711-8 71. de la Iglesia-Larrad J.I., Barral C., Casado-Espada N.M., de Alarcón R., Maciá- Casas A., Vicente Hernandez B. et al. Benzodiazepine abuse, misuse, dependence, and withdrawal among schizophrenic patients: a review of the literature. Psychiatry Res. 2020. 284:112660. doi: 10.1016/j.psychres.2019.112660 72. Verdoux H., Quiles C., Bon L., Chereau-Boudet I., Dubreucq J., Fiegi L. et al. Impact of anticholinergic load on functioning and cognitive performances of persons with psychosis referred to psychosocial rehabilitation centers. Psychol Med. 2020. 51:1–9. doi: 10.1017/S0033291720001403 73. Beck E.M., Cavelti M., Kvrgic S., Kleim B., Vauth R. Are we addressing the ’right stuff’ to enhance adherence in schizophrenia? Understanding the role of insight and attitudes towards medication. Schizophr Res. 2011. 132:42–49. doi: 10.1016/j.schres.2011.07.019 74. Kao Y.C., Liu Y.P. Compliance and schizophrenia: the predictive potential of insight into illness, symptoms, and side effects. Compr Psychiatry. 2010. 51:557–565. doi: 10.1016/j.comppsych.2010.03.007 75. Velligan D.I., Sajatovic M., Hatch A., Kramata P., Docherty J.P. Why do psychiatric patients stop antipsychotic medication? A systematic review of reasons for nonadherence to medication in patients with serious mental illness. Patient Prefer Adherence. 2017. 11:449–468. doi: 10.2147/PPA.S124658 76. Nielsen R.E., Levander S., Kjaersdam Telléus G., Jensen S.O., Østergaard Christensen T., Leucht S. Second-generation antipsychotic effect on cognition in patients with schizophrenia–a meta-analysis of randomized clinical trials. Acta Psychiatr Scand. 2015. 131:185–196. doi: 10.1111/acps.12374 77. Gabay A.S., Kempton M.J., Mehta M.A. Facial affect processing deficits in schizophrenia: a meta-analysis of antipsychotic treatment effects. J Psychopharmacol. 2015. 29:224–229. doi: 10.1177/0269881114560184 78. Zhang J.P., Gallego J.A., Robinson D.G., Malhotra A.K., Kane J.M., Correll C.U. Efficacy and safety of individual second-generation vs. first-generation antipsychotics in first-episode psychosis: a systematic review and meta-analysis. Int J Neuropsychopharmacol. 2013. 16:1205–1218. doi: 10.1017/ S1461145712001277 79. Rodewald K., Holt D.V., Rentrop M., Roesch-Ely D., Liebrenz M., Funke J. et al. Predictors for improvement of problem-solving during cognitive remediation for patients with Schizophrenia. J Int Neuropsychol Soc. 2014. 20:455–460. doi: 10.1017/S1355617714000162 80. Vita A., Deste G., De Peri L., Barlati S., Poli R., Cesana B.M. et al. Predictors of cognitive and functional improvement and normalization after cognitive remediation in patients with schizophrenia. Schizophr Res. 2013. 150:51–57. doi: 10.1016/j.schres.2013.08.011 81. Leong I. Side effects of olanzapine worsened by metabolic dysfunction. Nat Rev Endocrinol. 2018. 14:129. doi: 10.1038/nrendo.2017.183 82. Galderisi S., De Hert M., Del Prato S., Fagiolini A., Gorwood P., Leucht S. et al. Identification and management of cardiometabolic risk in subjects with schizophrenia spectrum disorders: a Delphi expert consensus study. Eur Psychiatry. 2021. 64:e7. doi: 10.1192/j.eurpsy.2020.115 83. Sykes D.A., Moore H., Stott L., Holliday N., Javitch J.A., Lane J.R. et al. Extrapyramidal side effects of antipsychotics are linked to their association kinetics at dopamine D(2) receptors. Nat Commun. 2017. 8:763. doi: 10.1038/s41467-017-00716-z 84. Ames D., Carr-Lopez S.M., Gutierrez M.A., Pierre J.M., Rosen J.A., Shakib S. et al. Detecting and managing adverse effects of antipsychotic medications: current state of play. Psychiatr Clin North Am. 2016. 39:275–311. doi: 10.1016/j.psc.2016.01.008 85. Fabrazzo M., Monteleone P., Prisco V., Perris F., Catapano F., Tortorella A. et al. Olanzapine is faster than haloperidol in inducing metabolic abnormalities in schizophrenic and bipolar patients. Neuropsychobiology. 2015. 72:29–36. doi: 10.1159/000437430 86. Galderisi S., Mucci A., Dollfus S., Nordentoft M., Falkai P., Kaiser S. et al. EPA guidance on assessment of negative symptoms in schizophrenia. Eur Psychiatry. 2021. 64:e23. doi: 10.1192/j.eurpsy. 2021.11 87. Galderisi S., Mucci A., Buchanan R.W., Arango C. Negative symptoms of schizophrenia: new developments and unanswered research questions. Lancet Psychiatry. 2018. 5:664–677. doi: 10.1016/S2215-0366(18)30050-6 88. De Hert M., Schreurs V., Vancampfort D., Van Winkel R. Metabolic syndrome in people with schizophrenia: a review. World Psychiatry. 2009. 8:15– 22. doi: 10.1002/j.2051-5545.2009.tb00199.x 89. Lindenmayer J.P., Khan A., Kaushik S., Thanju A., Praveen R., Hoffman L. et al. Relationship between metabolic syndrome and cognition in patients with schizophrenia. Schizophr Res. 2012. 142:171–176. doi: 10.1016/j.schres.2012.09.019 90. Li C., Zhan G., Rao S., Zhang H. Metabolic syndrome and its factors affect cognitive function in chronic schizophrenia complicated by metabolic syndrome. J Nerv Ment Dis. 2014. 202:313–318. doi: 10.1097/NMD. 0000000000000124 91. Bora E., Akdede B.B., Alptekin K. The relationship between cognitive impairment in schizophrenia and metabolic syndrome: a systematic review and meta-analysis. Psychol Med. 2017. 47:1030–1040. doi: 10.1017/S0033291716003366 92. Papola D., Ostuzzi G., Gastaldon C., Morgano G.P., Dragioti E., Carvalho A.F. et al. Antipsychotic use and risk of life-threatening medical events: umbrella review of observational studies. Acta Psychiatr Scand. 2019. 140:227–243. doi: 10.1111/acps.13066 93. Stroup T.S., Gray N. Management of common adverse effects of antipsychotic medications. World Psychiatry. 2018. 17:341–356. doi: 10.1002/wps.20567 94. Gupta S., Lakshmanan D.A.M., Khastgir U., Nair R. Management of antipsychotic-induced hyperprolactinaemia. BJPsych Advances. 2017. 23:278–286. doi: 10.1192/apt.bp.115.014928 95. Fabrazzo M., Prisco V., Sampogna G., Perris F., Catapano F., Monteleone A. et al. Clozapine versus other antipsychotics during the first 18 weeks of treatment: a retrospective study on risk factor increase of blood dyscrasias. Psychiatry Res. 2017. 256:275–282. doi: 10.1016/j.psychres.2017.06.068 96. Ogino S., Miyamoto S., Miyake N., Yamaguchi N. Benefits and limits of anticholinergic use in schizophrenia: focusing on its effect on cognitive function. Psychiatry Clin Neurosci. 2014. 68:37–49. doi: 10.1111/pcn.12088 97. O’Reilly K., O’Connell P., Donohoe G., Coyle C., O’Sullivan D., Azvee Z. et al. Anticholinergic burden in schizophrenia and ability to benefit from psychosocial treatment programmes: a 3-year prospective cohort study. Psychol Med. 2016. 46:3199–3211. doi: 10.1017/S00332917160 02154 98. Kim S.J., Jung D., Shim J.C., Moon J.J., Jeon D.W., Kim Y.N. et al. The effect of anticholinergic burden on cognitive and daily living functions in patients with schizophrenia. Asian J Psychiatr. 2019. 46:111–117. doi: 10.1016/j.ajp. 2019.10.013 99. Ang M.S., Abdul Rashid N.A., Lam M., Rapisarda A., Kraus M., Keefe R.S.E. et al. The impact of medication anticholinergic burden on cognitive performance in people with schizophrenia. J Clin Psychopharmacol. 2017. 37:651–65 6. doi: 10.1097/JCP.0000000000000790 100. Frydecka D., Beszłej J.A., Go´scimski P., Kiejna A., Misiak B. Profiling cognitive impairment in treatment-resistant schizophrenia patients. Psychiatry Res. (2016) 235:133–138. doi: 10.1016/j.psychres.2015.11.028 101. Eum S., Hill S.K., Rubin L.H., Carnahan R.M., Reilly J.L., Ivleva E.I. et al. Cognitive burden of anticholinergic medications in psychotic disorders. Schizophr Res. 2017. 190:129–135. doi: 10.1016/j.schres.2017.03.034 102. Fond G., Godin O., Dumontaud M., Faget C., Schürhoff F., Berna F. et al. Sexual dysfunctions are associated with major depression, chronic inflammation and anticholinergic consumption in the real-world schizophrenia FACE-SZ national cohort. Prog Neuro-Psychopharmacol Biol Psychiatry. 2019. 94:109654. doi: 10.1016/j.pnpbp.2019.109654 103. Morken G., Widen J.H., Grawe R.W. Non-adherence to antipsychotic medication, relapse and rehospitalisation in recent-onset schizophrenia. BMC Psychiatry. 2008. 8:32. doi: 10.1186/1471-244X-8-32 104. Kane J.M., Garcia-Ribera C. Clinical guideline recommendations for antipsychotic long-acting injections. Br J Psychiatry Suppl. 2009. 52:S63–67. doi: 10.1192/bjp.195.52.s63 105. Amore M., Murri M.B., Calcagno P., Rocca P., Rossi A., Aguglia E. et al. The association between insight and depressive symptoms in schizophrenia: undirected and Bayesian network analyses. European Psychiatry. 2020. 63:e46. doi: 10.1192/j.eurpsy.2020.45 106. Jeste S.D., Patterson T.L., Palmer B.W., Dolder C.R., Goldman S., Jeste D.V. Cognitive predictors of medication adherence among middle-aged and older outpatients with schizophrenia. Schizophr Res. 2003. 63:49–58. doi: 10.1016/S0920-9964(02)00314-6 107. Keith S.J., Kane J.M. Partial compliance and patient consequences in schizophrenia: our patients can do better. J Clin Psychiatry. 2003. 64:1308–1315. doi: 10.4088/JCP.v64n1105 108. Hudson T.J., Owen R.R., Thrush C.R., Han X., Pyne J.M., Thapa P. et al. A pilot study of barriers to medication adherence in schizophrenia. J Clin Psychiatry. 2004. 65:211–216. doi: 10.4088/JCP.v65n0211 109. Tattan T.M., Creed F.H. Negative symptoms of schizophrenia and compliance with medication. Schizophr Bull. 2001. 27:149–155. doi: 10.1093/oxfordjournals.schbul.a006853 110. Hasan A., Falkai P., Wobrock T., Lieberman J., Glenthoj B., Gattaz W.F. et al. World Federation of Societies of Biological Psychiatry (WFSBP) Guidelines for Biological Treatment of Schizophrenia, part 1: update 2012 on the acute treatment of schizophrenia and the management of treatment resistance. World J Biol Psychiatry. 2012. 3:318–378. doi: 10.3109/15622975.2012.696143 111. Leporini C., De Sarro G., Russo E. Adherence to therapy and adverse drug reactions: is there a link? Expert Opin Drug Saf. 2014. 13(Suppl. 1):S41–55. doi: 10.1517/14740338.2014.947260 112. Lähteenvuo M., Tiihonen J. Antipsychotic polypharmacy for the management of schizophrenia: evidence and recommendations. Drugs. 2021. 81:1273–1284. doi: 10.1007/s40265-021-01556-4 113. Remington G., Kwon J., Collins A., Laporte D., Mann S., Christensen B. The use of electronic monitoring (MEMS) to evaluate antipsychotic compliance in outpatients with schizophrenia. Schizophr Res. 2007. 90:229–237. doi: 10.1016/j.schres.2006.11.015 114. Marcum Z.A., Gellad W.F. Medication adherence to multidrug regimens. Clin Geriatr Med. 2012. 28:287–300. doi: 10.1016/j.cger.2012.01.008 115. Zelko E., Klemenc-Ketis Z., Tusek-Bunc K. Medication adherence in elderly with polypharmacy living at home. a systematic review of existing studies. Mater Sociomed. 2016. 28:129–132. doi: 10.5455/msm.2016.28.129-132 116. Hashimoto Y., Uno J., Miwa T., Kurihara M., Tanifuji H., Tensho M. Effects of antipsychotic polypharmacy on side-effects and concurrent use of medications in schizophrenic outpatients. Psychiatry Clin Neurosci. 2012. 66:405– 410. doi: 10.1111/j.1440-1819.2012.02376.x 117. Chapman S.C., Horne R. Medication nonadherence and psychiatry. Curr Opin Psychiatry. 2013. 26:446–452. doi: 10.1097/YCO.0b013e3283642da4 118. Johansen R., Iversen V.C., Melle I., Hestad K.A. Therapeutic alliance in early schizophrenia spectrum disorders: a cross-sectional study. Ann Gen Psychiatry. 2013. 12:14. doi: 10.1186/1744-859X-12-14 119. Ishii M., Okumura Y., Sugiyama N., Hasegawa H., Noda T., Hirayasu Y. et al. Efficacy of shared decision making on treatment satisfaction for patients with first- admission schizophrenia: study protocol for a randomised controlled trial. BMC Psychiatry. 2014. 14:111. doi: 10.1186/1471-244X-14-111 120. Fiorillo A., Barlati S., Bellomo A., Corrivetti G., Nicolò G., Sampogna G. et al. The role of shared decision-making in improving adherence to pharmacological treatments in patients with schizophrenia: a clinical review. Ann Gen Psychiatry. 2020. 19:43. doi: 10.1186/s12991-020-00293-4 121. Ishii M., Okumura Y., Sugiyama N., Hasegawa H., Noda T., Hirayasu Y. et al. Feasibility and efficacy of shared decision making for first-admission schizophrenia: a randomized clinical trial. BMC Psychiatry. 2017. 17:52. doi: 10.1186/s12888-017-1218-1 122. Mucci A., Kawohl W., Maria C., Wooller A. Treating schizophrenia: open conversations and stronger relationships through psychoeducation and shared decision-making. Front Psychiatry. 2020. 11:761. doi: 10.3389/fpsyt.2020.00761 123. Huang C., Lam L., Zhong Y., Plummer V., Cross W.. Chinese mental health professionals’ perceptions of shared decision-making regarding people diagnosed with schizophrenia: a qualitative study. Int J Ment Health Nurs. 2021. 30:189–199. doi: 10.1111/inm.12771_1 124. Vega D., Acosta F.J., Saavedra P. Testing the hypothesis of subtypes of nonadherence in schizophrenia and schizoaffective disorder: a prospective study. World J Psychiatry. 2020. 10:260–271. doi: 10.5498/wjp.v10.i11.260 125. Harris B.A., Panozzo G. Therapeutic alliance, relationship building, and communication strategies-for the schizophrenia population: an integrative review. Arch Psychiatr Nurs. 2019. 33:104–111. doi: 10.1016/j.apnu .2018.08.003 126. Green M.F., Lee J., Wynn J.K. Experimental approaches to social disconnection in the general community: can we learn from schizophrenia research? World Psychiatry. 2020. 19:177–178. doi: 10.1002/wps.20734 127. Lysaker P.H., Hasson-Ohayon I. Metacognition in psychosis: a renewed path to understanding of core disturbances and recovery-oriented treatment. World Psychiatry. 2021. 20:359–361. doi: 10.1002/wps.20914 128. Harvey P.D. When does cognitive decline occur in the period prior to the first episode of schizophrenia? Psychiatry. 2009. 6:12–14. 129. Dauwan M., Begemann M.J.H., Slot M.I.E., Lee E.H.M., Scheltens P., Sommer I.E.C. Physical exercise improves quality of life, depressive symptoms, and cognition across chronic brain disorders: a transdiagnostic systematic review and meta-analysis of randomized controlled trials. J Neurol. 2021. 268:1222–1246. doi: 10.1007/s00415-019-09493-9 130. Fernández-Abascal B., Suárez-Pinilla P., Cobo-Corrales C., Crespo-Facorro B., Suárez-Pinilla M. In- and outpatient lifestyle interventions on diet and exercise and their effect on physical and psychological health: a systematic review and metaanalysis of randomised controlled trials in patients with schizophrenia spectrum disorders and first episode of psychosis. Neurosci Biobehav Rev. 2021. 125:535–168. doi: 10.1016/j.neubiorev.2021.01.005 131. Millman L.S.M., Terhune D.B., Hunter E.C.M., Orgs G. Towards a neurocognitive approach to dance movement therapy for mental health: a systematic review. Clin Psychol Psychother. 2021. 28:24–38. doi: 10.1002/ cpp.2490 132. Bucci P., Mucci A., van Rossum I.W., Aiello C., Arango C., Baandrup L. et al. Persistent negative symptoms in recent-onset psychosis: relationship to treatment response and psychosocial functioning. Eur Neuropsychopharmacol. 2020. 34:76– 86. doi: 10.1016/j.euroneuro.2020.03.010 133. Moritz S., Silverstein S.M., Dietrichkeit M., Gallinat J. Neurocognitive deficits in schizophrenia are likely to be less severe and less related to the disorder than previously thought. World Psychiatry. 2020. 19:254–255. doi: 10.1002/wps.20759 134. Gaebel W., Falkai P., Hasan A. The revised German evidence- and consensus-based schizophrenia guideline. World Psychiatry. 2020. 19:117–119. doi: 10.1002/wps.20706 135. Sanislow C.A. RDoC at 10: changing the discourse for psychopathology. World Psychiatry. 2020. 19:311–312. doi: 10.1002/wps.20800 136. Giordano G.M., Brando F., Pezzella P., De Angelis M., Mucci A., Galderisi S. Factors influencing the outcome of integrated therapy approach in schizophrenia: A narrative review of the literature Frontiers in Psychiatry. 2022. Volume 13; 1-17. 10.3389/fpsyt.2022.970210 137. Kotov R., Jonas K.G., Carpenter W.T., Dretsch M.N., Eaton N.R., Forbes M.K. et al. Validity and utility of hierarchical taxonomy of psychopathology (HiTOP): I. Psychosis superspectrum. World Psychiatry. 2020. 19:151–172. doi: 10.1002/wps.20730 138. First M.B., Gaebel W., Maj M., Stein D.J., Kogan C.S., Saunders J.B. et al. An organization- and category-level comparison of diagnostic requirements for mental disorders in ICD-11 and DSM-5. World Psychiatry. 2021 .20:34–51. doi: 10.1002/wps.20825 139. Lahey B.B., Moore T.M., Kaczkurkin A.N., Zald D.H. Hierarchical models of psychopathology: empirical support, implications, and remaining issues. World Psychiatry. 2021. 20:57–63. doi: 10.1002/wps.20824 140. Krueger R.F., Hobbs K.A., Conway C.C., Dick D.M., Dretsch M.N., Eaton N.R. et al. Validity and utility of hierarchical taxonomy of psychopathology (HiTOP): II. Externalizing superspectrum. World Psychiatry. 2021. 20:171–193. doi: 10.1002/wps.20844 141. Giordano G.M., Bucci P., Mucci A., Pezzella P., Galderisi S. Gender differences in clinical and psychosocial features among persons with schizophrenia: a mini review. Front Psychiatry. 2021. 12:789179. doi: 10.3389/fpsyt.2021. 789179 142. Giordano G.M., Stanziano M., Papa M., Mucci A., Prinster A., Soricelli A. et al. Functional connectivity of the ventral tegmental area and avolition in subjects with schizophrenia: a resting state functional MRI study. Eur Neuropsychopharmacol. 2018. 28:589–602. doi: 10.1016/j.euroneuro.2018.03.013 143. Mucci A., Merlotti E., Üçok A., Aleman A., Galderisi S. Primary and persistent negative symptoms: concepts, assessments and neurobiological bases. Schizophr Res. 2017. 186:19–28. doi: 10.1016/j.schres.2016.05.014 144. Kirkpatrick B., Mucci A., Galderisi S. Primary, enduring negative symptoms: an update on research. Schizophr Bull. 2017. 43:730–736. doi: 10.1093/schbul/sbx064 145. Huhn M., Nikolakopoulou A., Schneider-Thoma J., Krause M., Samara M., Peter N. et al. Comparative efficacy and tolerability of 32 oral antipsychotics for the acute treatment of adults with multi-episode schizophrenia: a systematic review and network meta-analysis. Lancet. 2019. 394:939–951. doi: 10.1016/S0140-6736(19)31135-3 146. Krause M., Huhn M., Schneider-Thoma J., Bighelli I., Gutsmiedl K., Leucht S. Efficacy, acceptability and tolerability of antipsychotics in patients with schizophrenia and comorbid substance use. A systematic review and meta-analysis. Eur Neuropsychopharmacol. 2019. 29:32–45. doi: 10.1016/j.euroneuro.2018.11.1105 147. Fusar-Poli P., Papanastasiou E., Stahl D., Rocchetti M., Carpenter W., Shergill S. et al. Treatments of negative symptoms in schizophrenia: meta-analysis of 168 randomized placebo-controlled trials. Schizophr Bull. 2015. 41:892–899. doi: 10.1093/schbul/sbu170 148. Leucht S., Corves C., Arbter D., Engel R.R., Li C., Davis J.M. Second-generation versus first-generation antipsychotic drugs for schizophrenia: a meta-analysis. Lancet. 2009. 373:31–41. doi: 10.1016/S0140-6736(08) 61764-X 149. Медведев В.Э. Лечение шизофрении современными атипичными антипсихотическими препаратами” (учебно-методическое пособие). - М.: ОАО “Конти-Принт”, 2014. – 72 с. 150. Fleischhacker W., Galderisi S., Laszlovszky I., Szatmári B., Barabássy Á., Acsai K. et al. The efficacy of cariprazine in negative symptoms of schizophrenia: post hoc analyses of PANSS individual items and PANSS-derived factors. Eur Psychiatry. 2019. 58:1–9. doi: 10.1016/j.eurpsy.2019.01.015 151. Krause M., Zhu Y., Huhn M., Schneider-Thoma J., Bighelli I., Nikolakopoulou A. et al. Antipsychotic drugs for patients with schizophrenia and predominant or prominent negative symptoms: a systematic review and meta-analysis. Eur Arch Psychiatry Clin Neurosci. 2018. 268:625–639. doi: 10.1007/s00406-018-0869-3 152. Németh G., Laszlovszky I., Czobor P., Szalai E., Szatmári B., Harsányi J. et al. Cariprazine versus risperidone monotherapy for treatment of predominant negative symptoms in patients with schizophrenia: a randomised, doubleblind, controlled trial. Lancet. 2017. 389:1103–1113. doi: 10.1016/ S0140-6736(17) 30060-0 153. Pharoah F., Mari J., Rathbone J., Wong W. Family intervention for schizophrenia. Cochrane Database Syst Rev. 2010. 12:Cd000088. doi: 10.1002/14651858.CD000088.pub3 154. Carpenter W.T. Primary psychosis: more to know, much more to do. World Psychiatry. 2021. 20:1–2. doi: 10.1002/wps.20807 155. Galderisi S., Giordano G.M. We are not ready to abandon the current schizophrenia construct, but should be prepared to do so. Schizophr Res. 2022. 242:30–34. doi: 10.1016/j.schres.2021.12.007 156. Kiss B., Horváth A., Némethy Z. et al. Cariprazine (RGH-188), a dopamine D(3) receptor-preferring, D(3)/D(2) dopamine receptor antagonist-partial agonist antipsychotic candidate: in vitro and neurochemical profile // J PharmacolExpTher. 2010. 333; 328–340. 157. Медведев В.Э. Карипразин – новый антипсихотик для лечения шизофрении. Современная терапия психических расстройств. 2019. 2; 22-29. 158. Шмуклер А.Б. Карипразин (реагила) - новый атипичный антипсихотик с уникальным спектром психотропной активности. Социальная и клиническая психиатрия. 2020. 30(1);.110. 159. Stahl S.M. Mechanism of action of cariprazine. CNS Spectrums. 2016. 21; 123–127. doi:10.1017/S1092852916000043 160. Keator D.B., Mukherjee J., Preda A., et al. Dopamine D2 and D3 receptor occupancy of cariprazine in schizophrenic patients. Schizophr Bull. 2009. 35(Suppl. 1);154. 161. Newman-Tancredi A. The importance of 5-HT1A receptor agonism in antipsychotic drug action: rationale and perspectives. CurrOpinInvestig Drugs. 2010. 11;802–812. 162. Kirschner N., Gemesi L.I., Vastag M. et al. In vitro metabolism of RGH-188. Drug Metab Rev. 2008. 40(Suppl. 1); 128–129. 163. Kapas M., Meszaros G.P., Yu B. et al. Comparison of the pharmacokinetic behaviour of RGH-188 in schizophrenic patients and healthy volunteers. EurNeuropsychopharmacol. 2008. 18(Suppl. 4); 433. 164. Meszaros G.P., Kapas M., Borsos M., et al. Pharmacokinetics of RGH-188, a new dopamine D3/D2 antagonist/partial agonist atypical antipsychotic, in healthy subjects. EurNeuropsychopharmacol. 2007. 217(Suppl. 4);451–452. 165. Горобец Л.Н., Литвинов А.В. Карипразин: нейроэндокринные и метаболические аспекты переносимости у больных с психическими расстройствами. Современная терапия психических расстройств. 2020. 3; 19-27. DOI: 10.21265/PSYPH.2020.79.49.003 166. Доровских И.В., Павлова Т.А., Шайдеггер Ю.М. Карипразин – современный антипсихотик с благоприятным нейроэндокринным профилем. Формулы Фармации. 2020:2(3).; 58-63. doi: 10.17816/phf46072 167. Абриталин Е.Ю., Медведев В.Э., Морозов П.В. Опыт применения карипразина в стационарной и амбулаторной психиатрической практике. Психиатрия и психофармакотерапия им. П.Б. Ганнушкина. 2020: 6; 25-30. 168. Карипразин: от теории к практике (Специальность «Психиатрия» 31.08.20) : Пособие для врачей / Под ред. В. Э. Медведева. — М.: ООО «СИНАПС», 2021. — 114 с.. 169. Медведев В.Э. Карипразин — современный препарат для лечения шизофрении и биполярного расстройства. Современная терапия психических расстройств. 2022;3:51-57. 170. Durgam S., Bose A., Starace A., et al. An evaluation of the safety and efficacy of cariprazine in patients with acute exacerbation of schizophrenia: a phase II, randomized clinical trial. Schizophr Res. 2014. 152; 450-457. 171. Lieberman J.A., Cutler A.J., Wan S. et al. Cariprazine in acute exacerbation of schizophrenia: a fixed-dose, randomised, double-blind, placebo- and active-controlled trial. EurNeuropsychopharmacol. 2013. 23(suppl 2); 477–478. 172. Kane J.M., Zukin S., Wang Y., Lu K., Ruth A., Nagy K. Efficacy and Safety of Cariprazine in Acute Exacerbation of Schizophrenia. Results From an International, Phase III Clinical Trial. J ClinPsychopharmacol. 2015. 35; 367–373. 173. Citrome L., Durgam S., Lu K. et al. The effect of cariprazine on hostility associated with schizophrenia: post hoc analyses from 3 randomized controlled trials. J Clin Psychiatry. 2016. 77 (1); 109–115. 174. Earley W., Durgam S., Lu K. et al. Safety and tolerability of cariprazine in patients with acute exacerbation of schizophrenia: a pooled analysis of four phase II/III randomized, double-blind, placebo-controlled studies. IntClinPsychopharmacol. 2017. 32 (6); 319–328. 175. Zhao M.J., Qin B., Wang J.B. et al. Efficacy and Acceptability of Cariprazine in Acute Exacerbation of Schizophrenia: Meta-Analysis of Randomized Placebo-Controlled Trials. J ClinPsychopharmacol. 2018.38 (1); 55–59. 176. Németh G., Laszlovszky I., Czobor P. et al. Cariprazine versus risperidone monotherapy for treatment of predominant negative symptoms in patients with schizophrenia: a randomised, double-blind, controlled trial. Lancet. 2017. 389 (10074); 1103–1113. http://dx.doi.org/10.1016/S0140-6736(17)30060-0 177. Németh B., Molnár A., Akehurst R. et al. Quality-adjusted life year difference in patients with predominant negative symptoms of schizophrenia treated with cariprazine and risperidone. J Comp Eff Res. 2017. 6 (8); 639–648. 178. Krause M., Zhu Y., Huhn M. et al. Antipsychotic drugs for patients with schizophrenia and predominant or prominent negative symptoms: a systematic review and meta-analysis. Eur Arch Psychiatry ClinNeurosci. 2018. 268(7); 625-639. doi: 10.1007/s00406-018-0869-3. 179. Laszlovszky I., Barabássy, Á. & Németh, G. Cariprazine, A Broad-Spectrum Antipsychotic for the Treatment of Schizophrenia: Pharmacology, Efficacy, and Safety. Adv Ther. 2021. 38; 3652–3673. https://doi.org/10. 1007/s12325-021-01797-5 180. Fleischhacker W.W., Marder S., Lu K. et al. Efficacy of cariprazine versus placebo across schizophrenia symptom domains: pooled analyses from 3 phase II/III trials. Poster presented at the annual meeting of the American Society of Clinical Psychopharmacology; Miami, Florida; June 22–25, 2015. 181. Fleischhacker W., Galderisi S., Laszlovszky I. et al. The efficacy of cariprazine in negative symptoms of schizophrenia: post hoc analyses of PANSS individual items and PANSS-derived factors. Eur Psychiatry. 2019;58:1–9. 182. Durgam S., Earley W., Li R. et al. Long-term cariprazine treatment for the prevention of relapse in patients with schizophrenia: A randomized, double-blind, placebo-controlled trial. Schizophr Res. 2016. 176 (2–3); 264–271. 183. Neill J.C., Grayson B., Kiss B., Gyertyán I., Ferguson P., Adham N. Effects of cariprazine, a novel antipsychotic, on cognitive deficit and negative symptoms in a rodent model of schizophrenia symptomatology. Eur Neuropsychopharmacol. 2016 Jan; 26(1): 3-14. doi: 10.1016/j.euroneuro.2015.11.016. 184. Marder S., Fleischhacker W.W., Earley W., Lu K., Zhong Y., Németh G., Laszlovszky I., Szalai E., Durgam S. Efficacy of cariprazine across symptom domains in patients with acute exacerbation of schizophrenia: Pooled analyses from 3 phase II/III studies. Eur Neuropsychopharmacol. 2019 Jan;29(1):127-136. doi: 10.1016/j.euroneuro.2018.10.008. 185. Csehi R., Dombi Z.B., Sebe B., Molnár M.J. Real-Life Clinical Experience With Cariprazine: A Systematic Review of Case Studies. Front Psychiatry. 2022 Mar 17;13:827744. doi: 10.3389/fpsyt.2022.827744. 186. Citrome L. Cariprazine in Schizophrenia: Clinical Efficacy, Tolerability, and Place in Therapy. AdvTher. 2013. Published online: January 28, DOI 10.1007/s12325-013-0006-7 187. Durgam S., Starace A., Li D. et al. An evaluation of the safety and efficacy of cariprazine in patients with acute exacerbation of schizophrenia: a phase II, randomized clinical trial. Schizophr Res. 2014. 152 ; 450–457. 188. Nasrallah H.A., Earley W., Cutler A.J. et al. The safety and tolerability of cariprazine in long-term treatment of schizophrenia: a post hoc pooled analysis. BMC Psychiatry. 2017. 17 (1); 305. 189. Cutler A.J., Durgam S., Wang Y. et al. Evaluation of the long-term safety and tolerability of cariprazine in patients with schizophrenia: results from a 1-year open-label study. CNS Spectrums. 2018. 23 (1); 39-50. DOI: 10.1017/S1092852917000220. 190. Citrome L. Cariprazine in Schizophrenia: Clinical Efficacy, Tolerability, and Place in Therapy. AdvTher. 2013. Published online: January 28, DOI 10.1007/s12325-013-0006-7 191. Citrome L., Durgam S., Lu K. et al. The effect of cariprazine on hostility associated with schizophrenia: post hoc analyses from 3 randomized controlled trials. J Clin Psychiatry. 2016. 77 (1); 109–115. 192. Earley W., Durgam S., Lu K. et al. Safety and tolerability of cariprazine in patients with acute exacerbation of schizophrenia: a pooled analysis of four phase II/III randomized, double-blind, placebo-controlled studies. IntClinPsychopharmacol. 2017. 32 (6);319–328. 193. Zhao M.J., Qin B., Wang J.B. et al. Efficacy and Acceptability of Cariprazine in Acute Exacerbation of Schizophrenia: Meta-Analysis of Randomized Placebo-Controlled Trials. J ClinPsychopharmacol. 2018. 38 (1); 55–59. 194. Reagila (cariprazine): assessment report. European Medicines Agency, 2017. Available from: http://www.ema.europa.eu 195. Rancans E., Dombi Z.B., Mátrai P., Barabássy Á., Sebe B., Skrivele I., Németh G. The effectiveness and safety of cariprazine in schizophrenia patients with negative symptoms and insufficient effectiveness of previous antipsychotic therapy: an observational study. Int Clin Psychopharmacol. 2021 May 1;36(3):154-161. doi: 10.1097/YIC.0000000000000351.